Containment Cosmetics Protein 
XTalks
JULY 26, 2023
Brevel , an Israeli startup specializing in the conversion of microalgae into alternative proteins, recently secured $18.5 The Tel Aviv-based startup will use the new funding to deliver an alternative protein source that is neutral in taste, highly functional, remarkably sustainable and accessible to the broader food industry.
FDA Law Blog
JULY 11, 2023
Koblitz — One of the most important questions FDA has to answer is whether a given product is appropriately characterized as a drug, biologic, device, food, cosmetic, or something entirely different. FDA further defined the term “protein” so that it includes any peptide product that has an amino acid sequence greater than 40 amino acids.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
FDA Law Blog
DECEMBER 8, 2022
labeling of major food allergens in bulk foods, dietary supplements, protein-free ingredients, and foods produced through genetic engineering); and. labeling of major food allergens in bulk foods, dietary supplements, protein-free ingredients, and foods produced through genetic engineering); and. Other technical labeling matters.
XTalks
SEPTEMBER 28, 2023
Parabens, which are also prevalent in cosmetics, can interfere with the regular operation of human hormonal systems, affecting both male and female reproductive health, development, fertility and birth results. Using rBST results in higher concentrations of insulin-like growth factor 1 (IGF-1), a protein typically present in milk.
XTalks
APRIL 14, 2021
Scientists used synthetic biology and computational protein design tools to develop an enzymatic process to transform red cabbage anthocyanins into their desired color. The US Food and Drug Administration (FDA) defines color additives as “any substance that imparts color to a food, drug, cosmetic, or the human body.
The Pharma Data
NOVEMBER 4, 2020
Ltd (“Juyou”), a biotechnology company that develops and sells medical and cosmetic skincare products, for the commercialization and development of Pliaglis ® in mainland China (the “License Agreement”). For additional information, please visit [link]. About Crescita Therapeutics Inc.
Roots Analysis
SEPTEMBER 9, 2024
Over the years, pharmaceutical companies have shifted their priorities from traditional interventions towards more advanced pharmacological strategies, such as protein therapeutics. Further, $400 billion is the anticipated sales of protein-based therapeutics in 2023. The mRNA is then translated into to form functional proteins.
Expert insights. Personalized for you.
97 
Let's personalize your content